SEPTInvestingStart Free

ARWR 10-K: SEC filing

Arrowhead Pharmaceuticals

Filed with the SEC on · accession 0000879407-26-000078

ARWR filed a 10-K (annual report) with the SEC on Nov 12, 2026. Arrowhead Pharmaceuticals filed its annual report on Form 10-K for fiscal year 2026, covering the period ended September 30, 2026. The stock moved -4.5% by the first close after the filing.

Summary of the filing

Arrowhead Pharmaceuticals filed its annual report on Form 10-K for fiscal year 2026, covering the period ended September 30, 2026. The filing includes financial statements, collaboration and license agreement disclosures with partners such as Sarepta, Novartis, Sanofi, GSK, Takeda, and Madrigal, and equity offering activity.

For details, click here →How to read a 10-K →

Key details

Collaboration and license partnerSarepta Therapeutics, Inc.
Collaboration and license partnerNovartis Pharma AG
Collaboration and license partnerSanofi
Collaboration and license partnerMadrigal Pharmaceuticals, Inc.
Collaboration and license partnerGlaxoSmithKline Intellectual Property Limited
Collaboration and license partnerTakeda Pharmaceuticals Company Incorporated
Variable interest entity / subsidiaryVisirna Therapeutics, Inc.

How ARWR stock reacted

Close before

$49.36

Nov 11, 2026

First close after

-4.48%

$47.15

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ARWR, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ARWR?

Click here

Frequently asked questions

What did ARWR file with the SEC on Nov 12, 2026?

ARWR filed a 10-K (SEC filing). Arrowhead Pharmaceuticals filed its annual report on Form 10-K for fiscal year 2026, covering the period ended September 30, 2026. The filing includes financial statements, collaboration and license agreement disclosures with partners such as Sarepta, Novartis, Sanofi, GSK, Takeda, and Madrigal, and equity offering activity.

How do I read a 10-K?

The yearly report: full audited financial statements, the business, its risks and what management thinks about the year. Start with "Management’s Discussion and Analysis" (MD&A): management explains the year in their own words. Read "Risk Factors" for new risks — compare with last year’s list.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-K (annual report): The yearly report: full audited financial statements, the business, its risks and what management thinks about the year.

How did ARWR stock react to this filing?

ARWR closed at $49.36 before the filing and $47.15 on Nov 12, 2026 (-4.48%).

Other ARWR SEC filings

Get alerts when ARWR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ARWR overviewARWR analysisARWR newsLatest SEC filings